Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma
NCT03639168Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in adenoid cystic carcinoma (ACC), sponsored by Fudan University. Primary endpoint: Overall Response Rate at 6 weeks. Started Jun 2018; status: completed.
02
Drugs
tucidinostat
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03639168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639168.